English | 日本語
English | 日本語
Search search
bubble
No results found.
Product search is not available.

First Trust NYSE® Arca® Biotechnology Index Fund

Ticker
FBT
NAV
info
The NAV represents the fund's net assets (assets less liabilities) divided by the fund's outstanding shares.
$169.30
Market Price
info
Fund shares are purchased and sold on an exchange at their market price rather than net asset value (NAV), which may cause the shares to trade at a price greater than NAV (premium) or less than NAV (discount).
$169.20
Pricing as of 10/28/2024
Overview
Performance
Pricing
Holdings
Distributions

Overview

Fund Objective & Strategy

The First Trust NYSE® Arca® Biotechnology Index Fund is an exchange-traded index fund. The investment objective of the Fund is to replicate as closely as possible, before fees and expenses, the price and yield of the NYSE® Arca® Biotechnology Index.

There can be no assurance that the Fund's investment objectives will be achieved.

Index Description According to the Index Provider

  • The NYSE® Arca® Biotechnology Index (“index”) is an equal dollar weighted index designed to measure the performance of 30 leading biotechnology companies classified within the Biotechnology sub-industry group of the ICE Uniform Sector Classification schema.
  • The Biotechnology sub-industry group includes:
    • The Biotech Therapeutics Sub-Industry: Companies engaged in the research and development of therapeutic treatments (including companies in the trial phase of therapeutic development), but are not focused on the commercialization and mass production of pharmaceutical drugs.
    • The Biotech Tools & Diagnostics Sub-Industry: Companies engaged in the production and provisioning of tools, systems or processes that enable biotechnology practices (including companies that provide assaying equipment, sequencing techniques or systems, DNA processing, or cellular processing).
  • To be included in the index, a common stock or depositary receipt must be listed on a qualifying U.S. securities exchange, and meet the size and liquidity standards of the index.
  • Eligible securities are then ranked in descending order based on the following factors. These three distinct ranks are then combined to yield one comprehensive rank based on their respective weights:
    • 50%: Net sales (revenue) over the last 12 months.
    • 25%: Ratio of net sales (revenue) to R&D (research and development) expenditures over the last 12 months.
    • 25%: Percentage change in R&D expenditures (over the last 12 months) from those three years prior.
  • The highest ranked 30 securities are selected for inclusion in the index.
    • Additionally, the total number of index constituents classified to the Biotech Tools & Diagnostics sub-industry is capped at 6 constituents. If the limit is reached, the lowest ranked Biotech Tools & Diagnostics constituents are replaced with the next highest ranked Biotech Therapeutics non-constituents until this rule is met.
  • The securities selected for inclusion in the index are equally weighted. Index composition changes during scheduled reconstitutions are also subject to certain buffers designed to limit turnover.
  • The index is reconstituted and rebalanced quarterly in January, April, July and October.

Fund Facts

CUSIP
33733E203
ISIN
US33733E2037
Exchange
NYSE Arca
Inception
6/19/2006
Inception Share Price
$20.00
Inception NAV
$20.00
Rebalance Frequency
Quarterly
Fiscal Year-End
12/31
Fund Type
Biotechnology
Intraday NAV
FBTIV
Investment Advisor
First Trust Advisors L.P.
Investor Servicing Agent
Bank of New York Mellon Corp

Current Fund Data

As Of 10/28/2024
Closing NAV
info
The NAV represents the fund's net assets (assets less liabilities) divided by the fund's outstanding shares.
$169.30
Closing Market Price
info
Fund shares are purchased and sold on an exchange at their market price rather than net asset value (NAV), which may cause the shares to trade at a price greater than NAV (premium) or less than NAV (discount).
$169.20
30-Day Median Bid/Ask Spread
info
The median bid-ask spread is calculated by identifying the national best bid and national best offer ("NBBO") for the fund as of the end of each 10 second interval during each trading day of the last 30 calendar days and dividing the difference between each such bid and offer by the midpoint of the NBBO. The median of those values is identified and that value is expressed as a percentage rounded to the nearest hundredth.
0.15%
Bid/Ask Midpoint
$169.40
Bid/Ask Premium
0.06%
Total Net Assets
$1,185,075,538
Outstanding Shares
7,000,002
Daily Volume
15,516
Average 30-Day Daily Volume
29,526
Closing Market Price 52-Week High/Low
$173.05 / $132.56
Closing NAV 52-Week High/Low
$173.11 / $132.65

Fees And Expenses

As Of 5/1/2024
Total Expense Ratio
0.56%
Net Expense Ratio
0.56%

Expenses are capped contractually at 0.60% per year, at least through 4/30/2025.

Performance

Hypothetical Growth of $10,000 Since Inception *

As Of 10/28/2024
download Download Export

Performance data quoted represents past performance. Past performance is not a guarantee of future results and current performance may be higher or lower than performance quoted. Investment returns and principal value will fluctuate and shares when sold or redeemed, may be worth more or less than their original cost.

Tracking Index: NYSE® Arca® Biotechnology Index

Month End Performance

As Of 9/30/2024
Fund Performance * 3 Month YTD 1 Year 3 Year 5 Year 10 Year Since Inception
Net Asset Value (NAV) 11.93% 9.04% 17.72% 1.24% 6.82% 6.53% 12.58%
Market Price 11.94% 9.13% 17.80% 1.27% 6.85% 6.53% 12.59%
               
Index Performance ** 3 Month YTD 1 Year 3 Year 5 Year 10 Year Since Inception
NYSE® Arca® Biotechnology Index 12.08% 9.50% 18.39% 1.67% 7.34% 7.03% 13.17%
Nasdaq Biotechnology™ Index 5.09% 9.79% 21.59% -1.30% 9.61% 5.87% 11.36%
S&P Composite 1500® Health Care Index 6.08% 14.01% 21.46% 7.44% 12.91% 11.15% 11.53%
S&P 500® Index 5.89% 22.08% 36.35% 11.91% 15.98% 13.38% 10.93%

Inception Date is 6/19/2006

Quarter End Performance

As Of 9/30/2024
Fund Performance * 3 Month YTD 1 Year 3 Year 5 Year 10 Year Since Inception
Net Asset Value (NAV) 11.93% 9.04% 17.72% 1.24% 6.82% 6.53% 12.58%
Market Price 11.94% 9.13% 17.80% 1.27% 6.85% 6.53% 12.59%
               
Index Performance ** 3 Month YTD 1 Year 3 Year 5 Year 10 Year Since Inception
NYSE® Arca® Biotechnology Index 12.08% 9.50% 18.39% 1.67% 7.34% 7.03% 13.17%
Nasdaq Biotechnology™ Index 5.09% 9.79% 21.59% -1.30% 9.61% 5.87% 11.36%
S&P Composite 1500® Health Care Index 6.08% 14.01% 21.46% 7.44% 12.91% 11.15% 11.53%
S&P 500® Index 5.89% 22.08% 36.35% 11.91% 15.98% 13.38% 10.93%

Inception Date is 6/19/2006

3 Year Statistics

As Of 9/30/2024
Standard Deviation
info
Standard Deviation is a measure of price variability (risk).
Alpha
info
Alpha is an indication of how much an investment outperforms or underperforms on a risk-adjusted basis relative to its benchmark.
Beta
info
Beta is a measure of price variability relative to the market.
Sharpe Ratio
info
Sharpe Ratio is a measure of excess reward per unit of volatility.
Correlation
info
Correlation is a measure of the similarity of performance.

* Performance data quoted represents past performance. Past performance is not a guarantee of future results and current performance may be higher or lower than performance quoted. Investment returns and principal value will fluctuate and shares when sold or redeemed, may be worth more or less than their original cost.

Returns do not represent the returns you would receive if you traded shares at other times. Market Price returns are determined by using the midpoint of the national best bid offer price ("NBBO") as of the time that the fund's NAV is calculated. Returns are average annualized total returns, except those for periods of less than one year, which are cumulative.

** Performance information for each listed index is for illustrative purposes only and does not represent actual fund performance. Indexes do not charge management fees or brokerage expenses, and no such fees or expenses were deducted from the performance shown. Indexes are unmanaged and an investor cannot invest directly in an index.

Nasdaq Biotechnology™ Index - The Index includes securities of NASDAQ-listed companies classified as either Biotechnology or Pharmaceuticals which also meet other eligibility criteria.

S&P Composite 1500® Health Care Index - The Index is a capitalization-weighted index of companies classified by GICS as health care within the S&P Composite 1500 Index.

S&P 500® Index - The Index is an unmanaged index of 500 companies used to measure large-cap U.S. stock market performance.

Pricing

Price History

As Of 10/28/2024
download Download Export

Bid/Ask Premium/Discount

As Of 10/28/2024
  2023 1/1/2024 - 3/31/2024 4/1/2024 - 6/30/2024 7/1/2024 - 9/30/2024
Days Traded at Premium 119 37 36 38
Days Traded at Discount 131 24 27 26

Holdings

Fund Characteristics

As Of 9/30/2024
Maximum Market Cap.
info
All market capitalization numbers are in USD Millions.
$173,133
Median Market Cap.
info
All market capitalization numbers are in USD Millions.
$15,544
Minimum Market Cap.
info
All market capitalization numbers are in USD Millions.
$2,360
Price/Book
4.43
Price/Cash Flow
27.90
Price/Sales
5.81

Top Holdings

As Of 10/28/2024
Exelixis, Inc.
3.68%
Catalyst Pharmaceuticals, Inc.
3.67%
Corcept Therapeutics Incorporated
3.61%
Sarepta Therapeutics, Inc.
3.55%
Gilead Sciences, Inc.
3.54%
argenx SE (ADR)
3.50%
Intra-Cellular Therapies, Inc.
3.44%
Alnylam Pharmaceuticals, Inc.
3.42%
Neurocrine Biosciences, Inc.
3.41%
BioMarin Pharmaceutical Inc.
3.38%

Excluding cash. Holdings are subject to change.

Distributions

Distribution History

download Download Export
Ex-Dividend Date
Record Date
Payable Date
Distribution Amount
Distribution Type
info
Ordinary distributions may include realized short-term capital gains and/or returns of capital. Final determination of the source and tax status of all distributions paid in the current year are to be made after year-end. The Fund will send you a Form 1099-DIV for the current year that will tell you how to report these distributions for federal income tax purposes.

The distribution history represents dividends that were paid by the Fund and is not a guarantee of the Fund's future dividend-paying ability.

You should consider the fund's investment objectives, risks, and charges and expenses carefully before investing. You can download a prospectus or summary prospectus, or contact First Trust Portfolios L.P. at 1-800-621-1675 to request a prospectus or summary prospectus which contains this and other information about the fund. The prospectus or summary prospectus should be read carefully before investing.

You could lose money by investing in a fund. An investment in a fund is not a deposit of a bank and is not insured or guaranteed. There can be no assurance that a fund's objective(s) will be achieved. Investors buying or selling shares on the secondary market may incur customary brokerage commissions. Please refer to each fund's prospectus and Statement of Additional Information for additional details on a fund's risks. The order of the below risk factors does not indicate the significance of any particular risk factor.

Unlike mutual funds, shares of the fund may only be redeemed directly from a fund by authorized participants in very large creation/redemption units. If a fund's authorized participants are unable to proceed with creation/redemption orders and no other authorized participant is able to step forward to create or redeem, fund shares may trade at a premium or discount to a fund's net asset value and possibly face delisting and the bid/ask spread may widen.

Biotechnology and pharmaceutical companies are subject to changing government regulation which could have a negative effect on the price, profitability and availability of their products and services. Biotechnology and pharmaceutical companies face increasing competition from generic drugs, termination of their patent protection and technological advances which render their products or services obsolete. The research and development costs required to bring a drug to market are substantial and may include a lengthy review by the government, with no guarantee that the product will ever be brought to market or show a profit. Many of these companies may not offer certain drugs or products for several years, and as a result, may have significant losses of revenue and earnings.

Current market conditions risk is the risk that a particular investment, or shares of the fund in general, may fall in value due to current market conditions. As a means to fight inflation, the Federal Reserve and certain foreign central banks have raised interest rates; however, the Federal Reserve has recently lowered interest rates and may continue to do so. Recent and potential future bank failures could result in disruption to the broader banking industry or markets generally and reduce confidence in financial institutions and the economy as a whole, which may also heighten market volatility and reduce liquidity. Ongoing armed conflicts between Russia and Ukraine in Europe and among Israel, Hamas and other militant groups in the Middle East, have caused and could continue to cause significant market disruptions and volatility within the markets in Russia, Europe, the Middle East and the United States. The hostilities and sanctions resulting from those hostilities have and could continue to have a significant impact on certain fund investments as well as fund performance and liquidity. The COVID-19 global pandemic, or any future public health crisis, and the ensuing policies enacted by governments and central banks have caused and may continue to cause significant volatility and uncertainty in global financial markets, negatively impacting global growth prospects.

A fund is susceptible to operational risks through breaches in cyber security. Such events could cause a fund to incur regulatory penalties, reputational damage, additional compliance costs associated with corrective measures and/or financial loss.

Depositary receipts may be less liquid than the underlying shares in their primary trading market and distributions may be subject to a fee. Holders may have limited voting rights, and investment restrictions in certain countries may adversely impact their value.

Equity securities may decline significantly in price over short or extended periods of time, and such declines may occur in the equity market as a whole, or they may occur in only a particular country, company, industry or sector of the market.

Health care companies may be affected by government regulations and government health care programs, increases or decreases in the cost of medical products and services and product liability claims, among other factors. Many health care companies are heavily dependent on patent protection, and the expiration of a company's patent may adversely affect that company's profitability. Health care companies are also subject to competitive forces that may result in price discounting, may be thinly capitalized and susceptible to product obsolescence.

An index fund will be concentrated in an industry or a group of industries to the extent that the index is so concentrated. A fund with significant exposure to a single asset class, or the securities of issuers within the same country, state, region, industry, or sector may have its value more affected by an adverse economic, business or political development than a broadly diversified fund.

A fund may be a constituent of one or more indices or models which could greatly affect a fund's trading activity, size and volatility.

There is no assurance that the index provider or its agents will compile or maintain the index accurately. Losses or costs associated with any index provider errors generally will be borne by a fund and its shareholders.

Large capitalization companies may grow at a slower rate than the overall market.

Market risk is the risk that a particular security, or shares of a fund in general may fall in value. Securities are subject to market fluctuations caused by such factors as general economic conditions, political events, regulatory or market developments, changes in interest rates and perceived trends in securities prices. Shares of a fund could decline in value or underperform other investments as a result. In addition, local, regional or global events such as war, acts of terrorism, spread of infectious disease or other public health issues, recessions, natural disasters or other events could have significant negative impact on a fund.

A fund faces numerous market trading risks, including the potential lack of an active market for fund shares due to a limited number of market makers. Decisions by market makers or authorized participants to reduce their role or step away in times of market stress could inhibit the effectiveness of the arbitrage process in maintaining the relationship between the underlying values of a fund's portfolio securities and a fund's market price.

An index fund's return may not match the return of the index for a number of reasons including operating expenses, costs of buying and selling securities to reflect changes in the index, and the fact that a fund's portfolio holdings may not exactly replicate the index.

Securities of non-U.S. issuers are subject to additional risks, including currency fluctuations, political risks, withholding, lack of liquidity, lack of adequate financial information, and exchange control restrictions impacting non-U.S. issuers.

A fund and a fund's advisor may seek to reduce various operational risks through controls and procedures, but it is not possible to completely protect against such risks. The fund also relies on third parties for a range of services, including custody, and any delay or failure related to those services may affect the fund's ability to meet its objective.

A fund that invests in securities included in or representative of an index will hold those securities regardless of investment merit and the fund generally will not take defensive positions in declining markets.

Pharmaceutical companies are subject to changing government regulation which could have a negative effect on the price, profitability and availability of their products and services. Regulations have been proposed to increase the availability and affordability of prescription drugs including proposals to increase access to generic drugs and to increase the rebates paid by drug manufacturers in exchange for Medicaid coverage of their products. Whether such proposals will be adopted cannot be predicted. In addition, such companies face increasing competition from existing generic drugs, the termination of their patent protection for certain drugs and technological advances which render their products or services obsolete. The research and development costs required to bring a drug to market are substantial and may include a lengthy review by the government, with no guarantee that the product will ever be brought to market or show a profit. In addition, the potential for an increased amount of required disclosure of proprietary scientific information could negatively impact the competitive position of these companies. Many of these companies may not offer certain drugs or products for several years, and as a result, may have significant losses of revenue and earnings.

High portfolio turnover may result in higher levels of transaction costs and may generate greater tax liabilities for shareholders.

The market price of a fund's shares will generally fluctuate in accordance with changes in the fund's net asset value ("NAV") as well as the relative supply of and demand for shares on the exchange, and a fund's investment advisor cannot predict whether shares will trade below, at or above their NAV.

Securities of small- and mid-capitalization companies may experience greater price volatility and be less liquid than larger, more established companies.

Trading on an exchange may be halted due to market conditions or other reasons. There can be no assurance that a fund's requirements to maintain the exchange listing will continue to be met or be unchanged.

First Trust Advisors L.P. (FTA) is the adviser to the First Trust fund(s). FTA is an affiliate of First Trust Portfolios L.P., the distributor of the fund(s).

Source ICE Data Indices, LLC ("ICE DATA"), is used with permission. "NYSE®" and "NYSE® Arca®" are service/trade marks of ICE Data Indices, LLC or its affiliates. These trademarks have been licensed, along with the NYSE® Arca® Biotechnology Index ("Index") for use by First Trust Advisors L.P. in connection with the First Trust NYSE® Arca® Biotechnology Index Fund (the "Product"). Neither First Trust Advisors L.P., First Trust Exchange Traded Fund (the "Trust") nor the Product, as applicable, is sponsored, endorsed, sold or promoted by ICE Data Indices, LLC, its affiliates or its Third Party Suppliers ("ICE Data and its Suppliers"). ICE Data and its Suppliers make no representations or warranties regarding the advisability of investing in securities generally, in the Product particularly, the Trust or the ability of the Index to track general market performance. Past performance of an Index is not an indicator of or a guarantee of future results. See the prospectus for a full copy of the disclaimer.

CUSIP identifiers have been provided by CUSIP Global Services, managed on behalf of the American Bankers Association by FactSet Research Systems Inc. and are not for use or dissemination in a manner that would serve as a substitute for any CUSIP service. The CUSIP Database, ©2024 CUSIP Global Services. "CUSIP" is a registered trademark of the American Bankers Association.
Not FDIC Insured • Not Bank Guaranteed • May Lose Value